AL
Insider
ARCH Venture Partners X, LLC
10% ownerARCH Venture Partners X, LLC (10% owner) filed 2 Form 4 reports as a reporting entity in the past 24 months (2 purchases, 0 sales), most often in Neumora Therapeutics, Inc. (NMRA). Across 2 priced purchase filings, the average 21-session return was -13.6% from execution and -9.8% from disclosure (delay-adjusted; derived). The largest single filing was $10.0M of PRME (3,030,300 sh × $3.30, as filed), executed Aug 1 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-13.6%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-9.8%
same 2 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells
Median delay
1d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$15.0M
shares × price, as filed
Last traded
Oct 27 2025
Filed Oct 29 2025
Median ADV $3.2M across their filed names
Open performance→Volume by month
Buys $15.0M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Not on file
1 filing
Sector per market data · by filing · past 24 months
Most traded names
NMRARecent filings
NMRAPURCHASE
Neumora Therapeutics, Inc.
View filing →
$5.0M1,915,700 sh × $2.61
Exec Oct 27 2025
Filed Oct 29 2025 · 7:19 PM ET PRMEPURCHASE Prime Medicine, Inc. View filing → $10.0M
3,030,300 sh × $3.30
Exec Aug 1 2025
Filed Aug 1 2025 · 7:18 PM ET